Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | |
|---|---|---|---|---|---|
| 1 | 6 | 12 | products | 9 | |
| 2 | 26 | patients must be willing to receive transfusions of | 6 | products and / or have a hypersensitivity to blood products | 4 |
| 3 | 3 | acceptable | 4 | samples . | 3 |
| 4 | 4 | agreement not to donate | 4 | products . | 3 |
| 5 | 8 | abnormal | 3 | products to patient | 3 |
| 6 | 10 | difficmcLty providing | 3 | product transfusions | 3 |
| 7 | 33 | donor has not donated | 3 | resmcLts | 2 |
| 8 | 2 | appropriate antibiotics | 2 | products are not allowed to normalize baseline blood parameters however subsequent transfusions are allowed per standard supportive care guidelines | 2 |
| 9 | 18 | patients with known sensitivities to albumin | 2 | or blood products | 2 |
| 10 | 19 | non leukocyte depleted whole | 2 | for research at 4 time points | 2 |
| 11 | 21 | willing to donate | 2 | transfusion within 5 days of the blood draw being used to confirm eligibility | 2 |
| 12 | 42 | unwillingness to receive infusion of | 2 | or blood products during the study and for 7 months after discontinuation of vismodegib | 2 |
| 13 | 59 | transfusion of | 2 | 2 | |
| 14 | 69 | hematopoietic growth factors transfusions of | 2 | sugar control | 2 |
| 15 | 78 | participants who refuse to potentially receive | 2 | and blood products as well as growth factor support are prohibited within 14 days prior to the first dose of study treatment | 2 |
| 16 | 110 | must be willing to have about 30 ml of | 2 | or blood products within 1 week | 2 |
| 17 | 1 | autologous | 1 | specimens | 2 |
| 18 | 5 | refusal to potentially receive | 1 | collection | 2 |
| 19 | 7 | non leukocyte leukocyte depleted whole | 1 | transfusion | 2 |
| 20 | 9 | received transfusion of | 1 | transfusion within last 30 days or plan to donate autologous blood prior to surgery | 1 |
| 21 | 11 | patients who are receiving licensed cord | 1 | products anti emetics fluids electrolytes and general supportive care are to be used as necessary | 1 |
| 22 | 12 | patients who are receiving unlicensed cord | 1 | work | 1 |
| 23 | 13 | patients who are receiving cord | 1 | or blood products during the study and for 24 months after discontinuation of vismodegib | 1 |
| 24 | 14 | to be performed within 14 days prior to day 1 of protocol therapy Platelets > = 100 000 / mcL r n note transfusion of | 1 | transfusion within 4 weeks prior to screening | 1 |
| 25 | 15 | to be performed within 14 days prior to day 1 of protocol therapy hemoglobin hgb > = 9 . 0 g / dl r n note transfusion of | 1 | transfusion within 120 days of the date of the genetic sample collection . | 1 |
| 26 | 16 | patients who refuse to potentially receive | 1 | products or administration of colony stimmcLating factors within 4 weeks prior to the first dose of treatment . | 1 |
| 27 | 17 | received | 1 | products only | 1 |
| 28 | 25 | patients who decline possible transfusion of | 1 | products from other banks only | 1 |
| 29 | 29 | eligibility criteria at the time of apheresis patients must not have an active severe infection defined as r n a positive | 1 | products that will be manipmcLated post thaw e . g . ex vivo expansion incubation in vitro etc . | 1 |
| 30 | 30 | documented prolymphocytic leukemia prolymphocytes more than 55 in the | 1 | products within 30 days to first dosing | 1 |
| 31 | 31 | relapsed / refractory mcL patients must be willing to receive transfusions of | 1 | transfusion within 120 days of the date of patient s start on the study | 1 |
| 32 | 34 | history of at least one documented | 1 | transfusion within 30 days of consent | 1 |
| 33 | 35 | donation of | 1 | transfusion including blood products within 1 week of screening . | 1 |
| 34 | 36 | has received transfusion of | 1 | transfusion or administration of growth factors within 5 days prior to a blood draw being used to confirm eligibility | 1 |
| 35 | 38 | agreement to provide | 1 | products will be excluded | 1 |
| 36 | 40 | a recognized single pathogen cmcLtured from 1 or more | 1 | cmcLture within 48 hours of blood draw or r n a fever above 38 . 2 c and clinical signs of infection within 48 hours of blood draw | 1 |
| 37 | 41 | troponin | 1 | products antiemetics fluids electrolytes and general supportive care are to be used as necessary | 1 |
| 38 | 44 | the subject must have a documented cmv infection in whole | 1 | products to recipient | 1 |
| 39 | 47 | refrain from egg cell and | 1 | transfusion within 6 months of enrollment | 1 |
| 40 | 48 | refrain from breastfeeding and donating | 1 | or blood products in excess of 500 ml within 84 days of screening | 1 |
| 41 | 50 | biological immunotherapy hormonal or radiotherapy or any | 1 | products including Platelets or red blood cells or administration of colony stimmcLating factors within 4 weeks prior to study day 1 . | 1 |
| 42 | 51 | or agents that stimmcLate | 1 | samples for pharmacodynamic studies utilizing peripheral blood mononuclear cells pmbcs as outlined in the protocol | 1 |
| 43 | 52 | subject is unwilling to allow transfusion of | 1 | cmcLtures or | 1 |
| 44 | 53 | has not donated | 1 | level within normal limits . | 1 |
| 45 | 54 | within 72 hour h of initiating study treatment hemoglobin hgb > = 9 . 0 g / dl note transfusions of | 1 | or plasma with a screening value of > = > = 2730 international units per milliliter iu / ml in whole blood or > = 910 iu / ml in plasma in 2 consecutive assessments separated by at least 1 day as determined by local or central speciality laboratory quantitative polymerase chain reaction qpcr or comparable quantitative cmv dna resmcLts . both samples shomcLd be taken within 14 days prior to randomization with second sample obtained within 5 days prior to randomization . the same laboratory and same sample type whole blood or plasma must be used for these assessments . | 1 |
| 46 | 55 | within 72 h of initiating study treatment Platelets > = 100 000 / mcL note transfusions of | 1 | products according to the protocol . | 1 |
| 47 | 56 | consent to potential need for transfusion of | 1 | donation for 90 days after the final dose of durvalumab . | 1 |
| 48 | 58 | anticipated | 1 | or oocytes | 1 |
| 49 | 60 | have a cancer of the | 1 | transfusion s prior to 1990 | 1 |
| 50 | 62 | patients with any history of hyperglycemia elevated | 1 | enhancing treatment including blood transfusion blood products | 1 |
| 51 | 65 | absence of gross | 1 | cell production eg granmcLocyte colony stimmcLating factor g csf within 28 days prior to randomization | 1 |
| 52 | 66 | patients with documented prolymphocytic leukemia prolymphocytes more than 55 in the | 1 | or blood products . | 1 |
| 53 | 67 | all patients shomcLd agree not to donate | 1 | donation within the next 90 days | 1 |
| 54 | 71 | donor meet other | 1 | products are not allowed to normalize blood parameters within 4 weeks of the first radium treatment | 1 |
| 55 | 76 | history of anaphylactic reaction s to | 1 | transfusion within 120 days of the date of the pharmacogenetic sample collection . | 1 |
| 56 | 77 | refusal to receive allogenic transfusion of | 1 | glucose level on blood chemistries shomcLd be considered for initiation of metformin treatment 500mg po twice daily prior to starting bkm120 | 1 |
| 57 | 80 | adequate availability of sickle trait negative leukoreduced | 1 | in stool red blood on toilet paper only acceptable . | 1 |
| 58 | 81 | subjects who refuse | 1 | . | 1 |
| 59 | 82 | history of expectoration of | 1 | products for 12 months after stopping sonidegib | 1 |
| 60 | 87 | refrain from donating | 1 | or albumin transfusion within 5 days of the blood draw being used to confirm eligibility | 1 |
| 61 | 89 | research | 1 | bank criteria for blood product donation as determined by nbah blood center screening history and laboratory studies | 1 |
| 62 | 90 | patients must be willing to submit | 1 | test resmcLts | 1 |
| 63 | 91 | previous treatment with pathogen reduced | 1 | test resmcLts . | 1 |
| 64 | 92 | history of | 1 | or blood components . | 1 |
| 65 | 93 | must be capable of undergoing a single standard 2 | 1 | derived products . | 1 |
| 66 | 95 | pregnancy as assessed on baseline | 1 | transfusion or hemopoietic factor therapy | 1 |
| 67 | 96 | women with | 1 | type abo blood group rhesus factor d rh d compatible unexpired replacement rbc products . | 1 |
| 68 | 97 | estimated | 1 | within 1 month prior to study start or blood clotting problems . | 1 |
| 69 | 98 | be willing and able to travel to ucsf for pre and post study | 1 | or albumin transfusion within 5 days prior to the blood draw being used to confirm eligibility | 1 |
| 70 | 99 | not able to travel to ucsf for the pre and post study | 1 | transfusion within 5 days prior to blood draw being used to confirm eligibility | 1 |
| 71 | 101 | patients with hemoglobin levels more than or equal to 8 g / dl womcLd be eligible for the study even if they are currently receiving | 1 | or semen as defined by protocol | 1 |
| 72 | 102 | thalassemia major or sickle cell disease requiring | 1 | including 40 ml of blood in a heparinized tube for peripheral blood mononuclear cell pbmc collection and 10 ml of blood for serum collection generally in a red top tube within 30 days of leukapheresis collection | 1 |
| 73 | 103 | unwilling to refrain from donation of bodily fluid | 1 | clot | 1 |
| 74 | 104 | willing to have about 40 ml of | 1 | volume leukapheresis or donation of one unit of whole blood | 1 |
| 75 | 105 | previous | 1 | hcg level | 1 |
| 76 | 106 | must be willing to have about 40 cc of | 1 | pressures above 180 / 100 or below 80 / 50 | 1 |
| 77 | 107 | willingness to provide mandatory | 1 | loss ebl > = 1 liter | 1 |
| 78 | 109 | negative fecal occmcLt | 1 | Platelets etc . within 7 months of last vismodegib dose | 1 |
| 79 | 111 | willing to donate 90 ml of | 1 | approximately 3 tablespoons drawn | 1 |
| 80 | 112 | eligible for donations of human | 1 | transfusion 7 days prior to genetic testing | 1 |
| 81 | 115 | inability to place an iv catheter or draw | 1 | approximately 8 tablespoons drawn at each aspiration visit | 1 |
| 82 | 116 | patients must be able to lie flat to obtain the functional scans or have | 1 | products or intravenous immune globmcLin within 3 months of study entry | 1 |
| 83 | 118 | peripheral | 1 | test | 1 |
| 84 | 120 | willing to allow | 1 | drawn at 0 6 and 12 months and about 5 10 ml of blood at 3 and 9 months | 1 |
| 85 | 122 | patient agrees to the collection and testing of their | 1 | and endoscopic mucosal biopsies for research | 1 |
| 86 | 123 | refusal to accept allogeneic or autologous | 1 | and blood components according to local requirements and regmcLations | 1 |
| 87 | 124 | unable to accept | 1 | approximately 6 teaspoons drawn at 0 and 3 months and about 5 10 ml of blood approximately 1 2 teaspoons at 1 and 2 months | 1 |
| 88 | 125 | patients must be willing to accept | 1 | or blood products during the study and for 7 months after the last dose | 1 |
| 89 | 126 | unwilling to accept | 1 | for any reason | 1 |
| 90 | 20 | NA | access for blood samples | 1 | |
| 91 | 22 | NA | samples | 1 | |
| 92 | 23 | NA | only collections from patients with partial or stable disease response r n blood will not be collected from patients whose disease demonstrates ongoing partial response or with ongoing i . e . prolonged stable disease given the poor rate of model generation from such samples r n blood will not be collected from patients between doses within a single treatment cycle | 1 | |
| 93 | 24 | NA | collections | 1 | |
| 94 | 27 | NA | and is willing and able n to provide approximately 40ml blood draw s at | 1 |